Pharmacology of Aminophylline for Acute Kidney Injury in Neonates
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/9/2018 |
| Start Date: | October 2014 |
| End Date: | May 2018 |
Acute kidney injury (AKI) in critically ill neonates is common and associated with
significant morbidity and mortality. No targeted therapeutic treatment strategies have been
established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic
conceptual framework, this project will examine the medication aminophylline as a potential
treatment approach for AKI.
significant morbidity and mortality. No targeted therapeutic treatment strategies have been
established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic
conceptual framework, this project will examine the medication aminophylline as a potential
treatment approach for AKI.
Inclusion Criteria:
- Neonate < 3 months post natal age
- Diagnosed with acute kidney injury (AKI)
- Receiving aminophylline for AKI treatment as per local standard of care.
Exclusion Criteria:
- Presence of anatomical renal anomaly based on postnatal evaluation of the patient
(hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic
kidney, or obstructive uropathy)
- Patient on renal replacement therapy
- Major genetic abnormalities (trisomy 13, 18 or 21).
We found this trial at
1
site
Click here to add this to my saved trials
